Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.
The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.
Positive
- Inclusion in widely-tracked Russell 2000® and Russell 3000® Indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund purchases
- Recognition of company's market capitalization growth to qualify for these indexes
Negative
- None.
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025.
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about
For more information on the Russell 3000® Index, the Russell 2000® index, and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When was Aclaris Therapeutics (ACRS) added to the Russell 2000 and Russell 3000 indexes?
What are the requirements for Aclaris Therapeutics to be included in the Russell indexes?
How much in assets are benchmarked against Russell US indexes?
What is Aclaris Therapeutics' main business focus?
How long will Aclaris Therapeutics remain in the Russell indexes?
